Israel’s CollPlant Biotechnologies and the US-based United Therapeutics Corporation are expanding their partnership to begin the production of 3D-printed kidneys, the companies announced on Monday.
The collaboration agreement combines CollPlant’s proprietary recombinant human collagen (rhCollagen) and BioInk technology with the regenerative medicine and organ manufacturing capabilities of United Therapeutics.
United Therapeutics has paid CollPlant $3 million to exercise an option to license, on an exclusive basis, CollPlant’s technology for 3D bioprinting of human kidneys. This expanded collaboration aims to reduce global organ shortages, potentially saving lives of millions of patients on kidney waiting lists.
“Organ shortages are an unmet global health need and by partnering with United Therapeutics for the past couple of years, we have made significant progress with this pivotal organ manufacturing initiative,” said CollPlant CEO Yehiel Tal.